## The disclosed datapoint is more than “early traction”—it signals a potential unit-economics inflection In its most recent disclosure, Mangoceuticals (MangoRx) said its **new $99/month all-inclusive injectable testosterone replacement therapy (TRT) program** is showing **336% month-over-month sales growth** alongside a **54% reduction in customer acquisition cost (CAC)** since the mid-December launch. ["$99/month All-Inclusive"](0001493152-26-007468|1) ["Month over month growth of 336%"](0001493152-26-007468|1) ["reducing customer acquisition costs by 54%"](0001493152-26-007468|1) ["launching in mid-December"](0001493152-26-007468|1) **Between the lines:** when growth and CAC move in opposite directions that quickly, it often implies the company is starting to find a **repeatable acquisition channel** (or a better converting offer), not merely buying short-term revenue with higher spend. ["optimize marketing efficiency"](0001493152-26-007468|1) --- ## Why the $99/month “all-in” construct matters (and why it’s not just pricing) The company explicitly frames the program as **all-inclusive—doctor visits/consultations, lab work/analysis, and medication (to the extent prescribed)**—which functionally bundles the key friction points that typically slow conversion in hormone-health telemedicine. ["includes all doctor visits"](0001493152-26-007468|1) ["lab work and analysis"](0001493152-26-007468|1) ["and the medication"](0001493152-26-007468|1) **Alpha angle:** bundling can create a cleaner value proposition that improves conversion *and* retention dynamics (i.e., a membership-like relationship rather than one-off purchases). That becomes particularly important in a category like TRT where ongoing monitoring and continuity are intrinsic to the treatment journey. ["streamlined telehealth delivery"](0001493152-26-007468|1) ["patient access"](0001493152-26-007468|1) --- ## CAC down 54% while scaling: a clue about operating leverage inside the telehealth funnel MangoRx attributes the momentum to demand plus efforts to **“optimize marketing efficiency”** and improve **“patient access through its proprietary telehealth platform.”** ["optimize marketing efficiency"](0001493152-26-007468|1) ["patient access"](0001493152-26-007468|1) ["proprietary telehealth platform"](0001493152-26-007468|1) This matters in context: in its latest 10-Q (for the quarter ended Sept. 30, 2025), the company described revenue pressure tied to **“issues involving the transition and migration”** from its original platform to a new telehealth platform. ["transition and migration"](0001493152-25-023640|0) **Between the lines:** if the platform transition created prior disruption, this disclosure reads like management signaling that the engine is now stabilizing—and that they’re beginning to harvest funnel efficiency gains (lower CAC) while pushing volume (sales growth). ["reducing customer acquisition costs"](0001493152-26-007468|1) ["issues involving the transition"](0001493152-25-023640|0) --- ## Strategic intent: management is explicitly telling you where future mix is headed MangoRx states it **expects TRT to be the “primary growth driver” going forward** and that it plans to keep investing in TRT offerings (including **injectable and oral formulations**), specifically referencing **PRIME by MangoRx, powered by Kyzatrex®** as part of that roadmap. ["TRT to be the primary growth driver"](0001493152-26-007468|1) ["including both injectable and oral formulations"](0001493152-26-007468|1) ["PRIME by MangoRx, powered by Kyzatrex®"](0001493152-26-007468|1) **Alpha angle:** this is a quiet but important “capital allocation” message—TRT is being elevated from one product line among many to *the* growth spear. If TRT continues to scale with improving CAC, mix shift alone could change how investors underwrite the business (from episodic DTC wellness SKUs toward a more recurring, protocol-driven care model). ["key strategic focus"](0001493152-26-007468|1) ["TRT as our key strategic focus"](0001493152-26-007468|1) --- ## A broader pattern: $99/month is becoming a standardized membership anchor across programs Notably, MangoRx previously disclosed it launched **MangoRx Direct and PeachesRx Direct** offering telehealth consultations and support for **$99 per month** (with medication separate in that program). ["programs are now live"](0001493152-25-022505|1) ["for $99 per month"](0001493152-25-022505|1) ["medication cost and fulfillment separate"](0001493152-25-022505|1) **Between the lines:** the injectable TRT program’s “all-inclusive $99/month” packaging looks like a deliberate evolution of the same membership price point—potentially simplifying messaging, improving cross-sell, and lowering friction across the portfolio (which can show up as CAC efficiency). ["priced at $99 per month"](0001493152-26-007468|1) ["$99 per month"](0001493152-25-022505|1) --- If you want, I can also pull the **single most relevant risk/caveat language** from the latest 10-Q to frame what would need to go right (and what could break) for this CAC + growth setup to persist. ["Form 10-Q"](0001493152-25-023640|0)

## The disclosed datapoint is more than “early traction”—it signals a potential unit-economics inflection In its most recent disclosure, Mangoceuticals (MangoRx) said its **new $99/month all-inclusive injectable testosterone replacement therapy (TRT) program** is showing **336% month-over-month sales growth** alongside a **54% reduction in customer acquisition cost (CAC)** since the mid-December launch. ["$99/month All-Inclusive"](0001493152-26-007468|1) ["Month over month growth of 336%"](0001493152-26-007468|1) ["reducing customer acquisition costs by 54%"](0001493152-26-007468|1) ["launching in mid-December"](0001493152-26-007468|1) **Between the lines:** when growth and CAC move in opposite directions that quickly, it often implies the company is starting to find a **repeatable acquisition channel** (or a better converting offer), not merely buying short-term revenue with higher spend. ["optimize marketing efficiency"](0001493152-26-007468|1) --- ## Why the $99/month “all-in” construct matters (and why it’s not just pricing) The company explicitly frames the program as **all-inclusive—doctor visits/consultations, lab work/analysis, and medication (to the extent prescribed)**—which functionally bundles the key friction points that typically slow conversion in hormone-health telemedicine. ["includes all doctor visits"](0001493152-26-007468|1) ["lab work and analysis"](0001493152-26-007468|1) ["and the medication"](0001493152-26-007468|1) **Alpha angle:** bundling can create a cleaner value proposition that improves conversion *and* retention dynamics (i.e., a membership-like relationship rather than one-off purchases). That becomes particularly important in a category like TRT where ongoing monitoring and continuity are intrinsic to the treatment journey. ["streamlined telehealth delivery"](0001493152-26-007468|1) ["patient access"](0001493152-26-007468|1) --- ## CAC down 54% while scaling: a clue about operating leverage inside the telehealth funnel MangoRx attributes the momentum to demand plus efforts to **“optimize marketing efficiency”** and improve **“patient access through its proprietary telehealth platform.”** ["optimize marketing efficiency"](0001493152-26-007468|1) ["patient access"](0001493152-26-007468|1) ["proprietary telehealth platform"](0001493152-26-007468|1) This matters in context: in its latest 10-Q (for the quarter ended Sept. 30, 2025), the company described revenue pressure tied to **“issues involving the transition and migration”** from its original platform to a new telehealth platform. ["transition and migration"](0001493152-25-023640|0) **Between the lines:** if the platform transition created prior disruption, this disclosure reads like management signaling that the engine is now stabilizing—and that they’re beginning to harvest funnel efficiency gains (lower CAC) while pushing volume (sales growth). ["reducing customer acquisition costs"](0001493152-26-007468|1) ["issues involving the transition"](0001493152-25-023640|0) --- ## Strategic intent: management is explicitly telling you where future mix is headed MangoRx states it **expects TRT to be the “primary growth driver” going forward** and that it plans to keep investing in TRT offerings (including **injectable and oral formulations**), specifically referencing **PRIME by MangoRx, powered by Kyzatrex®** as part of that roadmap. ["TRT to be the primary growth driver"](0001493152-26-007468|1) ["including both injectable and oral formulations"](0001493152-26-007468|1) ["PRIME by MangoRx, powered by Kyzatrex®"](0001493152-26-007468|1) **Alpha angle:** this is a quiet but important “capital allocation” message—TRT is being elevated from one product line among many to *the* growth spear. If TRT continues to scale with improving CAC, mix shift alone could change how investors underwrite the business (from episodic DTC wellness SKUs toward a more recurring, protocol-driven care model). ["key strategic focus"](0001493152-26-007468|1) ["TRT as our key strategic focus"](0001493152-26-007468|1) --- ## A broader pattern: $99/month is becoming a standardized membership anchor across programs Notably, MangoRx previously disclosed it launched **MangoRx Direct and PeachesRx Direct** offering telehealth consultations and support for **$99 per month** (with medication separate in that program). ["programs are now live"](0001493152-25-022505|1) ["for $99 per month"](0001493152-25-022505|1) ["medication cost and fulfillment separate"](0001493152-25-022505|1) **Between the lines:** the injectable TRT program’s “all-inclusive $99/month” packaging looks like a deliberate evolution of the same membership price point—potentially simplifying messaging, improving cross-sell, and lowering friction across the portfolio (which can show up as CAC efficiency). ["priced at $99 per month"](0001493152-26-007468|1) ["$99 per month"](0001493152-25-022505|1) --- If you want, I can also pull the **single most relevant risk/caveat language** from the latest 10-Q to frame what would need to go right (and what could break) for this CAC + growth setup to persist. ["Form 10-Q"](0001493152-25-023640|0)